A Singular Vision
Relentless pursuit of transformative therapies targeting FcRn, a central mediator in autoimmune responses.
Rapid clinical advancement across multiple indications for our lead investigational candidate SYNT001.
FcRn plays a central role across a wide swath of autoimmune diseases affecting millions of people worldwide.
NEWS & PROGRESS
JULY 9, 2018
Syntimmune strengthens leadership team with appointment of chief medical officer
@syntimmune | JULY 9, 2018
We're glad to welcome veteran biopharma executive Mario Saltarelli, M.D., Ph.D., as our CMO. He brings broad experi… https://t.co/MY3CQiEJlN